MENU
+Compare
XOMAP
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$25.80
Change
+$0.15 (+0.58%)

XOMAP stock forecast, quote, news & analysis

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health... Show more

XOMAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for XOMAP with price predictions
Jun 27, 2025

XOMAP in upward trend: 10-day moving average crossed above 50-day moving average on June 26, 2025

The 10-day moving average for XOMAP crossed bullishly above the 50-day moving average on June 26, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where XOMAP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 24, 2025. You may want to consider a long position or call options on XOMAP as a result. In of 115 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for XOMAP just turned positive on June 25, 2025. Looking at past instances where XOMAP's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

XOMAP moved above its 50-day moving average on June 27, 2025 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

XOMAP broke above its upper Bollinger Band on June 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). XOMAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.084) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XOMAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XOMAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Dividends

XOMAP is expected to pay dividends on July 15, 2025

XOMA Corp XOMAP Stock Dividends
A dividend of $0.54 per share will be paid with a record date of July 15, 2025, and an ex-dividend date of July 03, 2025. The last dividend of $0.54 was paid on April 15. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 31.65 to 299.85B. NONOF holds the highest valuation in this group at 299.85B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 13%. RKVTD experienced the highest price growth at 1,028%, while KLTO experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 55%. For the same stocks of the Industry, the average monthly volume growth was 73% and the average quarterly volume growth was 137%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: 9 (-100 ... +100)
View a ticker or compare two or three
XOMAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2200 Powell Street
Phone
+1 510 204-7200
Employees
13
Web
https://www.xoma.com